Impact of Postnatal Corticosteroid Use on Neurodevelopment at 18 to 22 Months' Adjusted Age: Effects of Dose, Timing, and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants
- 1 March 2009
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 123 (3), e430-e437
- https://doi.org/10.1542/peds.2008-1928
Abstract
OBJECTIVE. Postnatal steroid use decreases lung inflammation but increases impairment. We hypothesized that increased dose is associated with increased neurodevelopmental impairment, lower postmenstrual age at exposure increases impairment, and risk of bronchopulmonary dysplasia modifies the effect of postnatal corticosteroid. METHODS. Steroid dose and timing of exposure beyond 7 days was assessed among 2358 extremely low birth weight infants nested in a prospective trial, with 1667 (84%) survivors examined at 18 to 22 months' postmenstrual age. Logistic regression tested the relationship between impairment (Bayley Mental Developmental Index/Psychomotor Developmental Index of n = 2336 (99%) for days of life 4–7). RESULTS. Three hundred sixty-six (16%) neonates were steroid-treated (94% dexamethasone). Treated neonates were smaller and less mature; 72% of those treated were at high risk for bronchopulmonary dysplasia. Exposure was associated with neurodevelopmental impairment/death. Impairment increased with higher dose; 71% dead or impaired at highest dose tertile. Each 1 mg/kg dose was associated with a 2.0-point reduction on the Mental Developmental Index and a 40% risk increase for disabling cerebral palsy. Older age did not mitigate the harm. Treatment after 33 weeks' postmenstrual age was associated with greatest harm despite not receiving the highest dose. The relationship between steroid exposure and impairment was modified by the bronchopulmonary dysplasia risk, with those at highest risk experiencing less harm. CONCLUSIONS. Higher steroid dose was associated with increased neurodevelopmental impairment. There is no “safe” window for steroid use in extremely low birth weight infants. Neonates with low bronchopulmonary dysplasia risk should not be exposed. A randomized trial of steroid use in infants at highest risk is warranted.This publication has 56 references indexed in Scilit:
- Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infantsArchives of Disease in Childhood: Fetal & Neonatal, 2007
- Critical Prenatal and Postnatal Periods for Persistent Effects of Dexamethasone on Serotonergic and Dopaminergic SystemsNeuropsychopharmacology, 2005
- Lasting Effects of Developmental Dexamethasone Treatment on Neural Cell Number and Size, Synaptic Activity, and Cell Signaling: Critical Periods of Vulnerability, Dose–Effect Relationships, Regional Targets, and Sex SelectivityNeuropsychopharmacology, 2005
- Effect of Decreased Use of Postnatal Corticosteroids on Morbidity in Extremely Low Birthweight InfantsAmerican Journal of Perinatology, 2005
- Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of PrematurityThe New England Journal of Medicine, 2004
- Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL surveyActa Paediatrica, 2003
- Association of Postnatal Dexamethasone Use and Fungal Sepsis in the Development of Severe Retinopathy of Prematurity and Progression to Laser Therapy in Extremely Low-Birth-Weight InfantsJournal of Perinatology, 2001
- Brain Corticosteroid Receptor Balance in Health and DiseaseEndocrine Reviews, 1998
- An in vivo/in vitro evaluation of teratogenic actionTeratology, 1981
- Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gmThe Journal of Pediatrics, 1978